Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Study of lncRNAs expression profile in the response to biological drugs in Psoriatic Arthritis: MEG3 could be a potential genomic biomarker of therapy efficacy.

International immunopharmacology - 15 Jun 2024

De Benedittis Giada, D'Antonio Arianna, Latini Andrea, Morgante Chiara, Conigliaro Paola, Triggianese Paola, Bergamini Alberto, Novelli Giuseppe, Ciccacci Cinzia, Chimenti Maria Sole, Borgiani Paola

Abstract excerpt

We aimed to identify an expression profile of lncRNAs potentially related to treatment response in Psoriatic arthritis (PsA) patients, to be used as potential genomic biomarkers predictors of drug treatment effectiveness. In addition, we evaluated a possible association between lncRNAs genetic variants and the response to therapy using the clinical parameter of Disease Activity Index. For the expression study, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antirheumatic Agents
Share to Arthritis, Psoriatic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biological Products

Share to Biomarkers

Share to Interleukin-17

Share to Polymorphism, Single Nucleotide

Share to RNA, Long Noncoding

Share to Treatment Outcome

Source

Identifiers

PMID: 38761785
DOI: 10.1016/j.intimp.2024.112239

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Study of lncRNAs expression profile in the response to biological drugs in Psoriatic Arthritis: MEG3 could be a potential genomic biomarker of therapy efficacy.PMID 38761785Read ↗

Comprehensive analyses of long non-coding RNA expression profiles by RNA sequencing and exploration of their potency as biomarkers in psoriatic arthritis patientsSemantic proximity Read ↗

Association between several immune response-related genes and the effectiveness of biological treatments in patients with moderate-to-severe psoriasis.Semantic proximity Read ↗

A distinct inflammatory gene expression profile in patients with psoriatic arthritisSemantic proximity Read ↗

Personalized medicine - a new reality in psoriatic arthritis?Semantic proximity Read ↗

Distinct genetic profile in peripheral blood mononuclear cells of psoriatic arthritis patients treated with methotrexate and TNF-inhibitors.Semantic proximity Read ↗

Serum MicroRNA Signature as a Diagnostic and Therapeutic Marker in Patients with Psoriatic ArthritisSemantic proximity Read ↗

New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis.Semantic proximity Read ↗

Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis.Semantic proximity Read ↗

Genetic prediction of the effectiveness of biologics for psoriasis treatment.Semantic proximity Read ↗

Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice.Semantic proximity Read ↗

Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis.Semantic proximity Read ↗

Gene expression profile predicting the response to anti-TNF treatment in patients with rheumatoid arthritis; analysis of GEO datasetsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.